FindTrial
Sign In

Nirmatrelvir/ritonavir

DRUG17 trials

Sponsors

UMC Utrecht, University of Oxford, Pfizer, Promomed, LLC, Chinese University of Hong Kong

Conditions

Biological AvailabilityCOVID-19COVID-19 Drug TreatmentCardiac SurgeryChronc Kidney Disease Stage 5Chronic Kidney Disease stage4Community-acquired Pneumonia, Influenza, COVID-19Coronavirus Disease 2019 (COVID-19)

Phase 1

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
CompletedNCT05525910
PfizerBiological Availability, Healthy Participants
Start: 2022-08-31End: 2022-11-07Updated: 2024-09-19
Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
CompletedNCT05544786
PfizerBiological Availability
Start: 2022-09-28End: 2022-11-29Updated: 2024-05-10
Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
CompletedNCT05544786
PfizerBiological Availability
Start: 2022-09-28End: 2022-11-29Updated: 2024-05-10
A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
CompletedNCT05898672
PfizerHealthy Volunteers, Pharmacokinetics
Start: 2023-06-09End: 2023-08-10Updated: 2024-10-28
A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants
WithdrawnNCT06397144
PfizerBiological Availability, Healthy Participants
Start: 2025-08-15End: 2025-12-09Updated: 2025-12-26

Phase 2

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
RecruitingNCT05041907
University of OxfordCOVID-19
Start: 2021-09-30End: 2027-01-01Target: 3800Updated: 2026-02-19
ImPROving Quality of LIFe in the Long COVID Patient
CompletedNCT05823896
Karolinska InstitutetCOVID-19, Long COVID, Long Covid19 +7
Start: 2023-05-01End: 2024-11-28Updated: 2024-12-04

Phase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
RecruitingNCT02735707
UMC UtrechtCommunity-acquired Pneumonia, Influenza, COVID-19
Start: 2016-04-11End: 2028-02-29Target: 20000Updated: 2024-07-12
Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population
CompletedNCT05601167
Promomed, LLCCOVID-19
Start: 2021-02-17End: 2022-06-01Updated: 2023-04-10
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway
Active, not recruitingNCT05852873
Haukeland University HospitalCOVID-19, Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection
Start: 2023-05-12End: 2027-06-11Target: 2000Updated: 2025-11-21

Phase 4

Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery
NCT05690646
China National Center for Cardiovascular DiseasesCardiac Surgery
Start: 2023-01-28End: 2026-01-06Updated: 2023-04-10
Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease
NCT05938140
Chinese PLA General HospitalCOVID-19, Renal Insufficiency, Chronic
Start: 2023-06-22End: 2025-05-30Target: 30Updated: 2023-07-10
Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial
RecruitingNCT06792214
Mount Sinai Hospital, CanadaSARS CoV-2 Post-Acute Sequelae
Start: 2025-01-03End: 2027-01-31Target: 118Updated: 2025-01-24

Unknown Phase

Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
CompletedNCT05624840
Chinese University of Hong KongChronc Kidney Disease Stage 5, Chronic Kidney Disease stage4, COVID-19
Start: 2022-11-07End: 2023-02-01Updated: 2024-02-07
Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19
CompletedNCT05813600
Xiangao JiangOmicron Variant of COVID-19
Start: 2022-08-31End: 2022-12-31Updated: 2023-04-14
Effectiveness and Safety of New Oral Antivirals for COVID-19
NCT05894603
Universidade do PortoCOVID-19
Start: 2022-08-01End: 2024-06-30Updated: 2023-12-18
A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco
WithdrawnNCT05997485
PfizerCOVID-19 Drug Treatment
Start: 2024-03-30End: 2024-06-30Updated: 2024-03-28
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
Not yet recruitingNCT07089680
PfizerCoronavirus Disease 2019 (COVID-19)
Start: 2025-08-18End: 2025-11-30Target: 1200Updated: 2025-07-28

Related Papers

LC-MS/MS Method Validation for Quantification of Nirmatrelvir in Human Plasma.
2025-11-17
Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial.
2025-11-06
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
2025-10-101 citations
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial
Thorax2025-05-139 citations
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia
Intensive Care Medicine2025-04-0132 citations
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV).
2025-01-183 citations
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection
JAMA Internal Medicine2024-06-0782 citations
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
2024-04-2410 citations
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
2024-01-1518 citations
A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial.
2023-12-068 citations
Simvastatin in Critically Ill Patients with Covid-19
New England Journal of Medicine2023-10-2559 citations
Intravenous Vitamin C for Patients Hospitalized With COVID-19
JAMA2023-10-2545 citations
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
2023-09-2852 citations
Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019
Clinical Infectious Diseases2023-08-0215 citations
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
The Journal of Infectious Diseases2023-07-1924 citations
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19
JAMA2023-04-1166 citations
The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors
The Journal of Infectious Diseases2023-03-274 citations
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
JAMA2023-03-2192 citations
The Impact of COVID-19 Research on the Development of Scalable Frameworks for Efficient Clinical Trials in Cardiovascular Medicine
Canadian Journal of Cardiology2023-03-153 citations
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)
eLife2023-02-0618 citations

16 more papers not shown